Aunins John G. 4
4 · Seres Therapeutics, Inc. · Filed Jan 29, 2019
Insider Transaction Report
Form 4
Aunins John G.
CTO and EVP of Bioprocess Dev.
Transactions
- Award
STOCK OPTION (RIGHT TO BUY)
2019-01-25+60,000→ 60,000 totalExercise: $6.01Exp: 2029-01-24→ Common Stock (60,000 underlying) - Exercise/Conversion
RESTRICTED STOCK UNITS
2019-01-26−7,500→ 12,500 total→ Common Stock (7,500 underlying) - Exercise/Conversion
COMMON STOCK
2019-01-26+7,500→ 92,750 total
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- [F3]These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020.